Infectious Disease · Medical Literature
[Correspondence] Shift in pre-existing antibiotic heteroresistance explains change in antimicrobial susceptibility status from susceptible to resistant during patient treatment
Abstract
Development of bacterial resistance during antibiotic therapy can lead to treatment failure and negative outcomes, including death. Although the development of resistance is observed relatively frequently, paradoxically, it is often thought to be mediated by rare mutations (frequency of ≤1 in 106)1 and is generally viewed as unpreventable. We describe a patient from the ALLIUM clinical trial with a complicated urinary tract infection caused by Klebsiella pneumoniae; the isolate was initially classified as susceptible to piperacillin–tazobactam (TZP, minimum inhibitory concentration 16/4 μg per mL)2 by broth microdilution (appendix p 3).
Clinical relevance
In a patient with complicated urinary tract infection caused by Klebsiella pneumoniae initially classified as susceptible to piperacillin–tazobactam, can the emergence of apparent clinical resistance during treatment be explained by selection from a pre-existing heteroresistant subpopulation rather than by de novo mutation? __SNAPSHOT__ {"studyDesign":"Case report / Correspondence (single patient from within a prospective randomized clinical trial — ALLIUM trial)","setting":"Patient derived from the ALLIUM randomized clinical trial (multicenter; specific institutional sites not reported in this abstract)","sampleSize":"n=1 (single patient case report)","population":"Adult patient enrolled in the ALLIUM clinical trial with a complicated urinary tract infection (cUTI) caused by Klebsiella pneumoniae, with a baseline isolate classified as susceptible to piperacillin–tazobactam (TZP) by broth microdilution (MIC 16/4 μg/mL)","intervention":"Piperacillin–tazobactam (TZP) treatment, with serial microbiological and molecular characterization of K. pneumoniae isolates obtained before and during therapy to assess population-level susceptibility via population analysis profiling (PAP) and evaluate for pre-existing heteroresistance","comparator":"Not applicable (single-arm case description; the comparison is intra-patient between baseline and on-treatment isolates)","primaryOutcome":"Determination of whether the shift in antimicrobial susceptibility classification from susceptible to resistant during TZP therapy is attributable to selection of a pre-existing heteroresistant subpopulation rather than acquisition of a de novo resistance mutation","followUp":"Duration of follow-up not reported; limited to the clinical course captured within the ALLIUM trial","fundingSource":"Not reported in the provided abstract; related prior work by overlapping authors was funded by the National Institute of Allergy and Infectious Diseases (NIAID), NIH (Heteroresistance Interdisciplinary Research Unit)"}
Key findings
The authors describe a single patient from the ALLIUM cUTI trial whose K. pneumoniae isolate was initially classified as susceptible to piperacillin–tazobactam (TZP) by broth microdilution (MIC 16/4 μg/mL, consistent with the susceptibility breakpoint). During the course of TZP therapy, the isolate's susceptibility classification shifted to resistant. The central observation is that this phenotypic change was explained not by the emergence of a new de novo mutation (which conventionally occurs at a frequency of ≤1 in 10⁶), but rather by enrichment of a pre-existing resistant subpopulation within a heteroresistant bacterial community — a phenomenon demonstrable by population analysis profiling (PAP). Specific quantitative effect sizes (e.g., fold-change in MIC, PAP AUC ratios, bacterial burden), p-values, and confidence intervals are not reported in the abstract. No NNT or NNH is calculable from these data. The clinical outcome of the patient (treatment success or failure, mortality) is not reported in the abstract.
Practice implications
This case report illustrates a mechanistically important concept: that apparent in-treatment development of antibiotic resistance — a phenomenon frequently observed in clinical practice and historically attributed to rare de novo mutations — may in at least some instances represent selective outgrowth of a pre-existing minority resistant subpopulation (heteroresistance) that is invisible to conventional broth microdilution susceptibility testing. Heteroresistance is defined as the coexistence of a predominantly susceptible bacterial population with a minority resistant subpopulation; because standard antimicrobial susceptibility testing measures bulk phenotype, these resistant subclones at frequencies as low as 1 in 10⁷ may go undetected. Prior laboratory and murine data from the same research group and others have demonstrated that heteroresistance to TZP in K. pneumoniae is often mediated by β-lactamase gene copy number amplification (e.g., tandem amplification of blaCTX-M-15, blaSHV, blaOXA-1, blaTEM-1) via mobile genetic elements or increased plasmid copy number. The present report extends this mechanistic framework to a documented clinical scenario within a controlled trial. What the study establishes: a plausible, molecularly coherent alternative mechanism for the susceptible-to-resistant transition during treatment in a single patient. What it does not establish: causality between heteroresistance and treatment failure, generalizability to other patients or pathogens, the frequency with which heteroresistance (vs. de novo mutation) accounts for in-treatment resistance emergence at the population level, or that any change in clinical practice is warranted based on a single case. The findings apply most directly to patients with TZP-susceptible K. pneumoniae infections in whom clinical or microbiological treatment failure occurs; patients not represented include those with non-Enterobacterales organisms, immunocompromised hosts (not specifically described), and those outside the cUTI clinical context. Because only an abstract was available for review, the completeness of the molecular data, the specific PAP methodology, the clinical details of treatment failure, and the breadth of supporting genomic evidence cannot be fully assessed. This is a hypothesis-generating single-case observation requiring prospective, adequately powered studies before any change in diagnostic or therapeutic practice. __LIMITATIONS__ Single patient case report: no statistical inference possible; findings cannot be generalized.,Correspondence format with abstract-only data available for review: full molecular characterization, PAP methodology, and clinical outcome data cannot be independently evaluated.,Absence of a control group or comparator patient population.,Clinical outcome (treatment failure, cure, mortality) of the index patient not reported in the abstract.,Causal inference is inherently limited: association between identified heteroresistance and clinical outcome is not established.,Patient selection from a clinical trial (ALLIUM) introduces potential selection bias; trial eligibility criteria may limit generalizability to real-world cUTI populations.,Broth microdilution MIC of 16/4 μg/mL is at the upper boundary of the susceptible range for TZP, which itself may represent a higher-risk susceptibility profile independent of heteroresistance.,Frequency with which pre-existing heteroresistance (vs. de novo mutation) accounts for in-treatment resistance emergence in broader populations is unknown and not addressed by a single case.,Potential funding and investigator bias cannot be assessed from the abstract alone.,PAP methodology is not yet standardized for routine clinical laboratory use, limiting immediate translational applicability. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This single-patient case report from the ALLIUM trial provides mechanistic evidence that susceptible-to-resistant transitions during piperacillin–tazobactam therapy for K. pneumoniae cUTI may reflect selection of pre-existing heteroresistant subpopulations rather than de novo mutation, a phenomenon invisible to standard susceptibility testing. The observation is hypothesis-generating and clinically intriguing but cannot support practice change; population-analysis profiling is not currently available in routine clinical laboratories. Clinicians should remain alert to the possibility of heteroresistance as an underappreciated contributor to treatment failure with TZP against K. pneumoniae, particularly when isolate MICs approach the susceptibility breakpoint.